New cocktail targets tough pancreatic cancer in early trial

NCT ID NCT06896188

Recruiting now Disease control Sponsor: Anwaar Saeed Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a three-part drug combination for people with advanced pancreatic cancer who haven't had chemotherapy yet. The drugs include elraglusib (a targeted agent), retifanlimab (an immunotherapy), and a standard chemo regimen called mFOLFIRINOX. The main goal is to check safety and find the right dose in up to 12 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Elraglusib (9-ING-41) combined with retifanlimab and chemotherapy (oxaliplatin, leucovorin, irinotecan, 5-FU)
What this could lead to: If this combination proves safe, it could point toward a more effective first-line treatment for advanced pancreatic cancer, potentially improving disease control.
What could go wrong: This is a very early phase 1 trial with only 12 patients, focused on safety. The drug combo may cause severe side effects or fail to shrink tumors. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hereditary sensory and autonomic neuropathy pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC ADENOCARCINOMA

Contacts and locations

Locations

UPMC Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.